Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

INTRODUCTION: BRAF mutations are rare in patients with NSCLC, and treatment options are limited. Dabrafenib plus trametinib (dab-tram) was approved for BRAF(V600)-mutated advanced NSCLC (aNSCLC), based on results from a phase 2 study (NCT01336634). This retrospective analysis compared the effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Bruce E., Baik, Christina S., Mazieres, Julien, Groen, Harry J.M., Melosky, Barbara, Wolf, Jürgen, Zadeh Vosta Kolaei, Fatemeh Asad, Wu, Wen-Hsing, Knoll, Stefanie, Ktiouet Dawson, Meryem, Johns, Adam, Planchard, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112112/
https://www.ncbi.nlm.nih.gov/pubmed/35592617
http://dx.doi.org/10.1016/j.jtocrr.2022.100324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112112/
https://www.ncbi.nlm.nih.gov/pubmed/35592617
http://dx.doi.org/10.1016/j.jtocrr.2022.100324

Ejemplares similares